Imagine using your regular company health check-up to catch serious diseases before they start. This project turns workplace clinics into hubs for spotting and treating common infections that often lead to cancer. It's like adding a high-impact filter to a routine check-up to save lives and reduce long-term medical costs.
Companies face high costs and productivity losses due to cancer, yet routine workplace health checks often ignore preventable infections. There is a lack of standardized, cost-effective protocols to integrate cancer screening into daily occupational health.
Standardized screening, vaccination, and treatment protocols for H. pylori, HCV, and HPV tailored for workplace implementation.
If you are a clinic network dealing with fragmented patient screening — this project developed standardized protocols for H. pylori and HCV that increase the volume of preventable cancer cases detected during routine visits.
If you are a plant operator dealing with high healthcare costs and worker absenteeism — this project developed screening and vaccination pathways for HPV and HCV that improve long-term workforce health.
If you are an insurer dealing with expensive late-stage cancer claims — this project developed cost-effectiveness models for early infection-related cancer prevention that reduce long-term payouts.
Based on available project data, specific pricing is not provided, but the project is explicitly assessing the cost-effectiveness of these interventions to demonstrate economic benefits.
Yes, the project is piloting these interventions across multiple European countries in sectors like manufacturing, retail, and finance to ensure large-scale adoption.
Based on available project data, there is no mention of specific patents or licenses; the project focuses on developing standardized protocols for public health adoption.
The protocols are designed to be incorporated into mandatory occupational health surveillance already required in European countries.
The project runs from May 2023 to April 2027, with the first phase already completing the design of screening and treatment protocols.
The consortium is well-balanced for market entry, featuring 19 partners across 7 countries. With a 26% industry ratio (5 companies, including 2 SMEs), the project blends academic rigor from 4 universities and 2 research centers with practical industrial application, ensuring the protocols are viable for actual workplace environments.
Contact the University of Bologna (ALMA MATER STUDIORUM) regarding the CPW project protocols.
Contact us to get the detailed cost-effectiveness data from the CPW pilots.
